The Food and Drug Administration posted its initial review of the drug MDMA on Friday, ahead of a meeting of outside advisers who could help decide whether it becomes the first of its kind to win US approval as a medication.
It comes as health regulators question the safety and evidence behind the first bid to use MDMA, the mind-altering club drug, as a treatment for PTSD.
